Gene: IGFBPL1
Official Full Name: insulin like growth factor binding protein like 1provided by HGNC
Gene Summary: Predicted to enable insulin-like growth factor binding activity. Involved in cellular response to tumor cell. Located in extracellular space. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO16984 | IGFBPL1 Knockout cell line (HeLa) | Human | IGFBPL1 | 1:3~1:6 | Negative | Online Inquiry |
KO16985 | IGFBPL1 Knockout cell line (HEK293) | Human | IGFBPL1 | 1:3~1:6 | Negative | Online Inquiry |
KO16986 | IGFBPL1 Knockout cell line (A549) | Human | IGFBPL1 | 1:3~1:4 | Negative | Online Inquiry |
IGFBPL1 Gene Knockout Cell Lines are genetically engineered cell lines designed to lack the insulin-like growth factor binding protein-like 1 (IGFBPL1) gene, a critical component in the regulation of insulin-like growth factors (IGFs) which are pivotal in various cellular processes including proliferation, differentiation, and survival. These knockout cell lines provide an invaluable tool for researchers investigating the specific roles of IGFBPL1 in metabolic signaling pathways and its effects on cellular responses.
The primary mechanism through which IGFBPL1 operates involves modulating the availability and activity of IGFs by binding to them and influencing their interaction with receptors on the cell surface. By using IGFBPL1 knockout cell lines, researchers can study the downstream effects of IGF signaling in a controlled environment, dissecting the implications of IGFBPL1 absence on cellular metabolism, growth, and apoptosis. This meticulous analysis is crucial for understanding the physiological and pathological roles of IGFBPL1 in conditions such as cancer, diabetes, and obesity.
In scientific and clinical research contexts, IGFBPL1 knockout cell lines serve as powerful models to elucidate cellular mechanisms and validate therapeutic targets. They provide a robust platform for drug discovery, enabling screening of compounds aimed at modulating IGF signaling pathways. Unlike conventional alternatives, these knockout lines enable precise investigations of gene function, circumventing the ambiguity present in partial knockdowns or overexpression systems.
The value of IGFBPL1 Gene Knockout Cell Lines lies in their ability to furnish researchers and clinicians with clear insights into IGFBPL1's contributions to health and disease. By facilitating a deeper understanding of IGF-related mechanisms, these cell lines drive advancements in therapeutic strategies, offering the potential for the development of more effective treatments for diseases linked to IGF dysregulation.
Our company specializes in providing high-quality biological products that empower researchers in their quest for scientific innovation. With rigorous quality control and comprehensive support, we ensure that our IGFBPL1 Gene Knockout Cell Lines are among the best in the industry, propelling your research to the frontiers of biological discovery.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.